# A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

> **NCT00626548** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 2577 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ZD4054
- **DRUG:** Palcebo

## Key facts

- **NCT ID:** NCT00626548
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-01
- **Final completion:** 2011-05
- **Target enrollment:** 2577 (ACTUAL)
- **Why stopped:** early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626548, "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00626548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*